Chong Kun Dang Pharmaceutical Corp (CKD Pharma) is a manufacturer of pharmaceutical products. The company’s product portfolio includes prescription products, over-the-counter (OTC) products, quasi drugs, health supplements, and consumer health products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

CKD Pharma maintains a robust R&D investment framework. The company has successfully advanced multiple self-developed and biosimilar therapeutics into commercialization and licensing deals, including CKD-510, Nesbell, Zaytech, and Lucenbs. Historical core products include Camptobell and Duvie. The company relies heavily on in-licensing to bolster its domestic therapeutic footprint, with major ongoing in-licensed assets such as ADC Platform Technology, CKD-101, Namodenoson, and Tedopi. To accelerate timeline efficiency and lower development expenditure, Chong Kun Dang actively leverages an open innovation network and infrastructural expansion, including the establishment of Acella Co., Ltd. and the acquisition of land for the Baegot Bio Complex. The R&D unit of Chong Kun Dang Pharmaceutical Corp. includes the newly established subsidiary, Acella Co., Ltd., which is responsible for optimizing research workflows. The company also plans to construct a state-of-the-art Bio Compound Research and Development Complex at the Baegot Bio Complex. The company has a pipeline of products that includes New Chemical Entities (NCEs) such as CKD-943, CKD-950, CKD-951, ACL-508 (CKD-508), CKD-510, CKD-512, ACL-513 (CKD-513), and ACL-514 (CKD-514), as well as biologics like CKD-703, CKD-704, and CKD-706. Major technology alliances include a non-exclusive platform technology license from Synaffix B.V. and licensing agreements with Curigin, Can-Fite Biopharma, and OSE Immunotherapeutics. In FY2025, the company spent KRW154,097.1 million on its R&D activities, which as a percentage of revenue stood at 9.1% and grew 7.1% YoY.